Loading
A phase 3 trial of Vepdegestrant and Palbociclib in advanced solid tumours, run by Pfizer, active and no longer recruiting.
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer is a phase 3 interventional study registered as NCT05909397 by Pfizer, with 59 participants enrolled, started 2023-08-09 and due to reach its primary completion in 2026-12-30. Interventions recorded: Vepdegestrant (ARV-471/PF-07850327), Palbociclib and Letrozole.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, CDK4/6 inhibitors, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.
Shares Vepdegestrant, PROTACs & molecular glues (targeted protein degradation), Endocrine therapy (SERMs, AIs, SERDs), Pfizer (incl. Seagen) and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen) and the tag pipeline.
Shares CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares CDK4/6 inhibitors, Pfizer (incl. Seagen), Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Palbociclib, CDK4/6 inhibitors, Endocrine therapy (SERMs, AIs, SERDs) and the tag pipeline.